Singh M, Raghav A, Gautam KA. Role of the circulatory interleukin-6 in the pathogenesis of gliomas: A systematic review. World J Methodol 2022; 12(5): 428-437 [PMID: 36186749 DOI: 10.5662/wjm.v12.i5.428]
Corresponding Author of This Article
Kirti Amresh Gautam, BSc, MSc, PhD, Assistant Professor, Department of Basic and Applied Science, GD Goenka University, Sohna Road, Gurugram 122103, Haryana, India. emails2kirti@gmail.com
Research Domain of This Article
Immunology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Methodol. Sep 20, 2022; 12(5): 428-437 Published online Sep 20, 2022. doi: 10.5662/wjm.v12.i5.428
Role of the circulatory interleukin-6 in the pathogenesis of gliomas: A systematic review
Manish Singh, Alok Raghav, Kirti Amresh Gautam
Manish Singh, Alok Raghav, Department of Neurosurgery, GSVM Medical College, Kanpur 208001, India
Kirti Amresh Gautam, Department of Basic and Applied Science, GD Goenka University, Gurugram 122103, Haryana, India
Author contributions: Singh M conceptualized this manuscript; Gautam KG and Raghav A performed the literature search and scrutiny of eligible studies; Gautam KG and Raghav A wrote the manuscript; all authors have read and approved the final draft of the manuscript.
Conflict-of-interest statement: All authors report no relevant conflict of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kirti Amresh Gautam, BSc, MSc, PhD, Assistant Professor, Department of Basic and Applied Science, GD Goenka University, Sohna Road, Gurugram 122103, Haryana, India. emails2kirti@gmail.com
Received: December 13, 2021 Peer-review started: December 13, 2021 First decision: March 24, 2022 Revised: April 1, 2022 Accepted: July 24, 2022 Article in press: July 24, 2022 Published online: September 20, 2022
Abstract
BACKGROUND
Glioma is the most common primary tumor in the brain originating from glial cells. In spite of extensive research, the overall survival rate is not enhanced. A number of published articles observed differentially circulating levels of cytokines in glioma. Interleukin-6 (IL-6) protein coded by IL-6 gene is regulated by the immune system and it has been found to have a significant role in progression and apoptosis resistance of glioma.
AIM
To review the role of circulatory IL-6 in the development and progression of glioma and its utility as a biomarker.
METHODS
Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines were applied to filter the relevant studies based on inclusion and exclusion criteria. We used a combination of keywords and the Reference Citation Analysis (RCA) tool to search the potential studies and performed data extraction from selected studies.
RESULTS
The published results were inconsistent; however, most studies showed a significantly higher IL-6 level in glioma cases as compared to controls. Comparative IL-6 level among the different grades of glioma showed a higher level with low-grade gliomas and lower level with high-grade gliomas.
CONCLUSION
IL-6 level significantly differed between cases and controls, and among different cancer stages, which shows its potential as a diagnostic and prognostic marker.
Core Tip: In spite of extensive research in the field of brain oncology, the overall survival is not much improved. There is an urgent need to explore the circulatory markers for diagnosis and prognosis. This systematic review focused on the role of interleukin-6 in brain cancer development and progression and its utility as a diagnostic or prognostic biomarker.
